Changes in expression of transforming growth factor beta mRNA isoforms in patients undergoing tamoxifen therapy
1997

Changes in TGF-beta mRNA in Breast Cancer Patients on Tamoxifen

publication Evidence: low

Author Information

Author(s): JR Benson, AA Colletta

Primary Institution: Department of Surgery, Chelsea and Westminster Hospital

Hypothesis

How do transforming growth factor beta isoforms change in breast cancer patients undergoing tamoxifen therapy?

Conclusion

The study suggests that variations in TGF-beta expression may not be a reliable indicator of therapeutic response due to methodological issues.

Supporting Evidence

  • Previous studies have shown mixed results regarding TGF-beta expression in breast cancer.
  • Some studies indicate that TGF-beta may be regulated differently in early versus advanced stages of cancer.
  • Immunohistochemical studies could provide more insight into TGF-beta protein levels.

Takeaway

This study looks at how a specific protein changes in breast cancer patients taking a medication called tamoxifen, but the results are complicated and hard to interpret.

Potential Biases

Potential bias due to the methodology allowing for significant intratumoral assay variation.

Limitations

The study's conclusions may be limited due to the age of participants and the size of their tumors.

Participant Demographics

Patients over 70 years of age with estrogen receptor positive tumors at least 3 cm in diameter.

Statistical Information

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication